Disclosed herein are methods for treatment for fibrosis, ocular pathologies associated with fibrosis, including proliferative vitreoretinopathy (PVR) by inhibiting the activity of activated transforming growth factor β activated kinase 1 (TAK1), or activation thereof. Pharmaceutical compositions for use in the described treatments are also provided.